UBT251 Injection China Phase II Clinical Study Results Presented atEASD 2026

SECOND MILESTONE PAYMENT FROM NOVO FOR EXCLUSIVE LICENSE AGREEMENT OF UBT251

THE GROUP’S PRODUCT INSULIN DEGLUDEC AND LIRAGLUTIDE INJECTION MARKETING REGISTRATION APPLICATION BEEN ACCEPTED

TUL ranked among the top 101 in the 2026 Pharmaceutical Industry, top 15 in API business, and top 20 in New Drug BD strength

UBT251 injection has been successfully included in the key variety list of the Greater Bay Area Center for Drug Evaluation and Inspection by the National Medical Products Administration

At Seoul CPHI, TUL deepens cooperation in the Korean market

The United Laboratories Animal Healthcare Co., Ltd. showcased at SIAVS Brazil Livestock Expo, delving deeper into overseas markets in Latin America

TUL ranks 30th in the "Top 100 Enterprises in China's Pharmaceutical Industry by Main Business Revenue in 2025"

Further expanding into the West African livestock market, The United Laboratories Animal Healthcare Co., Ltd. showcased at the 2026 AVIANA West Africa International Agricultural and Livestock Expo in Nigeria